
Genetic cholesterol eliminated by new drug, reducing heart attack risk, study finds
Fox News
A new Cleveland Clinic study found that an experimental drug eliminates elevated levels of lipoprotein(a) or Lp(a), which has been linked to higher risk of heart attack or stroke.
Elevated Lp(a) cannot be modified with lifestyle changes, and has been called "one of the last untreatable frontiers of cardiovascular risk" by Cleveland Clinic, who led the study. "Lp(a) is an independent risk factor for heart disease that is largely determined by genetics." "Whatever your level is when you're 24 years old is the level when you're 64 years old – it doesn't change, because it's genetic."
This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can "silence" the main gene responsible for synthesizing Lp(a).